A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells

References

• Anvari K, Seilanian TM, Bahadorkhan G, et al. (2014). Treatment outcomes and prognostic factors in pediatric non-brainstem astrocytoma in North East of Iran. Iran J Cancer Prev 7:96–100
   PubMedGoogle Scholar
• Boggs K, Reisman D. (2007). C/EBP beta participates in regulating transcription of the p53 gene in response to mitogen stimulation. J Biol Chem 282:7982–90
   Google Scholar
• Choi EJ, Kim GH. (2009). Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J Nutr Biochem 20:285–90
   PubMed Web of Science ®Google Scholar
• Du J, Lu WL, Ying X, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood–brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6:905–17
   PubMed Web of Science ®Google Scholar
• Fu A, Wang Y, Zhan L, Zhou R. (2012). Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharm Res 29:1562–9
   PubMed Web of Science ®Google Scholar
• Fu A, Zhang M, Gao F, et al. (2013). A novel peptide delivers plasmids across blood–brain barrier into neuronal cells as a single-component transfer vector. PLoS One 8:e59642
   PubMed Web of Science ®Google Scholar
• Fu A, Zhao Z, Gao F, Zhang M. (2013). Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells. Pharm Res 30:2108–17
   PubMed Web of Science ®Google Scholar
• Goh AM, Coffill CR, Lane DP. (2011). The role of mutant p53 in human cancer. J Pathol 223:116–26
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. (2009). Cytoplasmic functions of the tumor suppressor p53, Nature 458:1127–30
   PubMed Web of Science ®Google Scholar
• Hansen JE, Fischer LK, Chan G, et al. (2007). Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res 67:1769–74
   PubMed Web of Science ®Google Scholar
• Heitz F, Morris MC, Divita G. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195–206
   PubMed Web of Science ®Google Scholar
• Ishii N, Maier D, Merlo A, et al. (1999). Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469–79
   PubMed Web of Science ®Google Scholar
• Li H, Tsui T. (2014). Six-cell penetrating peptide-based fusion proteins for siRNA delivery. Drug Deliv. Early Online: 1–8. doi: 10.3109/10717544.2014.881439
   Web of Science ®Google Scholar
• Li X, Luo J, Wang S, et al. (2010). Engineering, expression, and immuno-characterization of recombinant protein comprising multi-neutralization sites of rabies virus glycoprotein. Protein Exp Purif 70:179–83
   PubMed Web of Science ®Google Scholar
• Lu X. (2005). p53: a heavily dictated dictator of life and death. Curr Opin Genet Dev 15:27–33
   PubMed Web of Science ®Google Scholar
• Mazarakis ND, Azzouz M, Rohll JB, et al. (2001). Rabies Virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10:2109–21
   PubMed Web of Science ®Google Scholar
• Nayak A, Ralte AM, Sharma MC, et al. (2004). p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 52:228–32
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–53
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2012). Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab 32:1959–72
   PubMed Web of Science ®Google Scholar
• Singh VK, Subudhi BB. (2014). Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. Drug Deliv 5:1–11
   Google Scholar
• Tang Q, Orciari LA, Rupprechti CE, et al. (2000). Sequencing and position analysis of the glycoprotein gene of four Chinese rabies viruses. Virol Sin 15:22–33
   Google Scholar
• Todorova R. (2011). Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics. Drug Deliv 8:586–98
   Web of Science ®Google Scholar
• Yamada T, Das Gupta TK, Beattie CW. (2013). P28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol Pharm 10:3375–83
   PubMed Web of Science ®Google Scholar
• Yan H, Liu N, Zhao Z, et al. (2012). Expression and purification of human TAT-p53 fusion protein in Pichia pastoris and its influence on HepG2 cell. Biotechnol Lett 34:1217–23
   PubMed Web of Science ®Google Scholar
• Yoshida K, Miki Y. (2010). The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 101:831–35
   PubMed Web of Science ®Google Scholar
• Yu Z, Wu J, Wu S, et al. (2009). A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth. Cancer Lett 279:101–7
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang EQ, Gao FY, et al. (2014). Effect of bifunctional RDP-BDNF fusion protein on ability of learning and memory of cognitive dysfunction mice induced by scopolamine. Chin Pharmacol Bull 30:1569–74
   Google Scholar
• Zhao B, Sun M, Liu T, et al. (2014). Effects of RDP-p53 fusion protein on inflammatory cytokine of mice. Sci Technol Eng 14:1–3
   Google Scholar